Stock listing
HKEX:2617 TransThera Sciences (Nanjing). Inc. (藥捷安康) 股價
Home listing (HKEX) of TransThera Sciences (Nanjing). Inc.
Follow TransThera Sciences (Nanjing). Inc. into a list and get an email when it puts out news.
Share price · HKEX:2617
$6.45 HKD -0.50 (-7.2%)
Close on Nov 20, 2026
- Day range
- $6.35 – $6.70 HKDNov 20, 2026
- Volume
- 2.52M sharesNov 20, 2026
- Market cap
- $2.02B HKDAt the close on Nov 20, 2026 · price × 312.5M shares outstanding
- 52-week range
- $6.35 – $217.20 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $42.54M HKDMedian day 3.13M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2617 · Home | $6.45 HKD | -0.50 (-7.2%) | 2,520,000 | $6.39 | $6.70 | $6.345 | $6.95 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2617 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.45 | -0.50 | -7.2% | $6.39 | $6.70 | $6.345 | 2,520,000 | |
| $6.95 | -0.18 | -2.5% | $7.165 | $7.275 | $6.92 | 2,135,010 | |
| $7.13 | -0.13 | -1.8% | $7.285 | $7.315 | $7.07 | 1,667,500 | |
| $7.26 | -0.315 | -4.2% | $7.80 | $7.80 | $7.22 | 2,101,000 | |
| $7.575 | -0.40 | -5.0% | $7.985 | $8.065 | $7.57 | 2,633,000 | |
| $7.975 | -0.18 | -2.2% | $8.39 | $8.39 | $7.925 | 2,487,500 | |
| $8.155 | -0.125 | -1.5% | $8.26 | $8.265 | $8.06 | 2,142,500 | |
| $8.28 | +0.24 | +3.0% | $8.19 | $8.30 | $8.13 | 1,958,780 | |
| $8.04 | -0.045 | -0.6% | $8.18 | $8.38 | $8.04 | 2,368,397 | |
| $8.085 | -0.26 | -3.1% | $8.11 | $8.235 | $8.045 | 2,450,500 | |
| $8.345 | +0.415 | +5.2% | $7.995 | $8.42 | $7.995 | 5,987,000 | |
| $7.93 | +0.12 | +1.5% | $7.99 | $8.055 | $7.71 | 3,782,500 | |
| $7.81 | -0.09 | -1.1% | $7.905 | $8.48 | $7.75 | 5,637,000 | |
| $7.90 | -0.50 | -6.0% | $8.565 | $8.565 | $7.53 | 4,968,000 | |
| $8.40 | -0.255 | -2.9% | $8.87 | $9.395 | $8.40 | 13,363,000 | |
| $8.655 | -0.055 | -0.6% | $8.80 | $9.18 | $8.62 | 4,707,500 | |
| $8.71 | +0.23 | +2.7% | $8.545 | $8.84 | $8.51 | 1,850,000 | |
| $8.48 | -0.385 | -4.3% | $8.98 | $8.98 | $8.42 | 2,845,500 | |
| $8.865 | +0.06 | +0.7% | $8.80 | $8.98 | $8.565 | 1,462,000 | |
| $8.805 | +0.265 | +3.1% | $8.55 | $9.00 | $8.35 | 3,363,000 | |
| $8.54 | -0.53 | -5.8% | $9.075 | $9.09 | $8.455 | 3,579,000 | |
| $9.07 | -0.025 | -0.3% | $9.245 | $9.315 | $9.05 | 1,517,500 | |
| $9.095 | -0.18 | -1.9% | $9.39 | $9.39 | $9.09 | 1,720,500 | |
| $9.275 | +0.14 | +1.5% | $9.33 | $9.70 | $9.20 | 4,337,500 | |
| $9.135 | -0.20 | -2.1% | $9.39 | $9.455 | $9.06 | 2,454,000 | |
| $9.335 | -0.275 | -2.9% | $9.685 | $9.69 | $9.335 | 1,924,000 | |
| $9.61 | -0.39 | -3.9% | $9.85 | $10.00 | $9.44 | 2,790,500 | |
| $10.00 | -0.43 | -4.1% | $10.48 | $10.64 | $9.915 | 3,151,500 | |
| $10.43 | +0.36 | +3.6% | $10.19 | $10.65 | $9.81 | 4,705,500 | |
| $10.07 | 0.00 | 0.0% | $10.47 | $10.68 | $9.97 | 4,320,500 | |
| $10.07 | -0.06 | -0.6% | $10.07 | $10.14 | $9.525 | 421,002 | |
| $10.13 | -0.09 | -0.9% | $10.28 | $10.46 | $10.13 | 365,500 | |
| $10.22 | -0.50 | -4.7% | $10.48 | $10.52 | $10.10 | 296,500 | |
| $10.72 | -0.22 | -2.0% | $10.59 | $10.72 | $10.09 | 647,500 | |
| $10.94 | +0.82 | +8.1% | $10.12 | $11.06 | $10.08 | 8,780,500 | |
| $10.12 | +0.06 | +0.6% | $10.10 | $10.24 | $9.98 | 1,916,500 | |
| $10.06 | +0.03 | +0.3% | $10.23 | $10.56 | $9.90 | 3,110,500 | |
| $10.03 | -0.30 | -2.9% | $10.48 | $10.48 | $9.86 | 496,500 | |
| $10.33 | -0.28 | -2.6% | $10.54 | $10.69 | $10.22 | 2,951,500 | |
| $10.61 | -0.14 | -1.3% | $10.85 | $11.49 | $10.55 | 12,522,500 | |
| $10.75 | -0.37 | -3.3% | $11.03 | $11.25 | $10.61 | 9,906,500 | |
| $11.12 | +1.09 | +10.9% | $10.38 | $11.73 | $10.24 | 35,768,000 | |
| $10.03 | +0.62 | +6.6% | $9.50 | $10.25 | $9.50 | 10,386,810 | |
| $9.41 | +0.05 | +0.5% | $9.58 | $9.59 | $9.295 | 2,514,500 | |
| $9.36 | -0.18 | -1.9% | $9.62 | $9.64 | $9.31 | 2,073,000 | |
| $9.54 | -0.03 | -0.3% | $9.615 | $9.88 | $9.54 | 3,396,000 | |
| $9.57 | +0.195 | +2.1% | $9.55 | $10.19 | $9.24 | 7,250,000 | |
| $9.375 | -0.085 | -0.9% | $9.425 | $9.49 | $9.01 | 3,498,500 | |
| $9.46 | +0.06 | +0.6% | $9.445 | $9.49 | $9.255 | 2,176,000 | |
| $9.40 | -0.285 | -2.9% | $9.80 | $9.80 | $9.38 | 3,406,500 | |
| $9.685 | -0.155 | -1.6% | $9.925 | $9.925 | $9.66 | 3,164,000 | |
| $9.84 | -0.31 | -3.1% | $10.15 | $10.22 | $9.79 | 5,293,000 | |
| $10.15 | +0.06 | +0.6% | $10.14 | $10.49 | $10.02 | 4,975,000 | |
| $10.09 | +0.06 | +0.6% | $10.16 | $10.24 | $9.975 | 2,486,000 | |
| $10.03 | -0.05 | -0.5% | $10.20 | $10.22 | $9.965 | 3,586,000 | |
| $10.08 | -0.09 | -0.9% | $10.17 | $10.25 | $10.06 | 1,783,000 | |
| $10.17 | -0.23 | -2.2% | $10.35 | $10.37 | $10.08 | 2,479,500 | |
| $10.40 | -0.14 | -1.3% | $10.74 | $10.74 | $10.25 | 3,599,500 | |
| $10.54 | +0.27 | +2.6% | $10.46 | $10.65 | $10.27 | 4,442,500 | |
| $10.27 | +0.08 | +0.8% | $10.25 | $10.54 | $10.25 | 3,349,000 | |
| $10.19 | +0.215 | +2.2% | $10.03 | $10.30 | $9.805 | 5,013,500 | |
| $9.975 | -0.335 | -3.2% | $10.38 | $10.43 | $9.95 | 3,268,500 | |
| $10.31 | -0.07 | -0.7% | $10.44 | $10.44 | $10.12 | 4,543,800 | |
| $10.38 | +0.33 | +3.3% | $10.51 | $10.88 | $10.33 | 19,557,000 |
- Ticker
- HKEX:2617
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- HKEX
- Currency
- HKD
What changed lately
Latest news release · Nov 19, 2026
Next Day Disclosure Return
Latest news
Next Day Disclosure Return
Nov 19, 2026
Closed $6.45 (-7.2%) on Nov 20, 2026
Inside information announcement completion of the H share full circulation
Nov 19, 2026
Closed $6.45 (-7.2%) on Nov 20, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 3, 2026
Closed $7.93 (+1.5%) on Nov 4, 2026
Inside information announcement grant of listing approval by the stock exchange for implementation of the h share full circulation
Nov 1, 2026
Closed $7.90 (-6.0%) on Nov 2, 2026
Inside information announcement issuance of the filing notice by the CSRC for the h share full circulation by the company
Oct 26, 2026
Closed $8.48 (-4.3%) on Oct 27, 2026
Voluntary announcement business update on commercialisation of core product Yochanra
Oct 22, 2026
Closed $8.54 (-5.8%) on Oct 22, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Oct 5, 2026
Closed $10.13 (-0.9%) on Oct 6, 2026
Interim report 2026
Sep 21, 2026
Closed $10.75 (-3.3%) on Sep 22, 2026
TransThera Sciences (Nanjing). Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 18 in all · newest Nov 19, 2026 · oldest 2025
Where TransThera Sciences (Nanjing). Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2617 藥捷安康 · Home listing · This page | HKEX | Hong Kong | HKD |
| Frankfurt:J8J | Frankfurt | Germany | EUR |
Valuation
Price/book 1.9× against a median of 2.0×: 5th lowest of 10 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $933.6M HKD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.5M | US$243.4M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Median of the others | US$258.6M | US$128.0M | 21.8× | 2.0× | −196.0% | 0.1× | 1.48 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.06 HKD · Analysts' mean
- EPS, year to Dec 2026
- -0.74 · 1 analyst
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 19, 2025 | −19.4% |
| Q1 2025 | Jun 9, 2025 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.18M | 124.0K | 61.8M | |
| Cost of revenue | 0 | 0 | 0 | 3.40M | ||
| Gross profit | 0 | 0 | 1.18M | 124.0K | -3.40M | |
| Research and development | 246.8M | 244.0M | 379.0K | 297.3K | 76.5M | 72.2M |
| Selling, general and administrative | 54.8M | 47.7M | 43.0K | 56.3K | ||
| Operating income | -300.2M | -286.7M | -390.5M | -312.3M | -43.9M | -98.4M |
| Depreciation and amortization | 5.03M | 6.44M | 7.40M | 8.91M | 4.59M | 3.40M |
| EBITDA | -295.2M | -280.2M | -383.1M | -303.4M | -39.3M | -95.0M |
| Interest expense | 121.0K | 201.0K | 248.5K | 184.9K | 37.8M | 16.4M |
| Income before tax | -296.0M | -274.6M | -350.6M | -251.9M | -74.5M | -110.9M |
| Income tax | 6.23M | |||||
| Net income | -296.0M | -274.6M | -344.1M | -250.0M | -80.7M | -110.9M |
| Earnings per share, basic | -0.76 | -0.69 | -902.26 | -693.80 | -0.20 | -0.28 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 415.4M | 569.5M | 496.6M | 1.11B | 78.2M | 27.8M |
| Short-term investments | 73.7M | 3.03M | 341.5M | 473.4K | 201.1M | |
| Receivables | 2.31M | 35.3M | 2.69M | |||
| Inventory | 212.0K | 173.0K | 160.0K | 277.5K | ||
| Current assets | 500.9M | 585.3M | 845.6M | 1.32B | 324.6M | 35.0M |
| Property, plant and equipment | 28.8M | 31.6M | ||||
| Total assets | 545.9M | 629.6M | 887.1M | 1.35B | 344.9M | 50.1M |
| Accounts payable | 104.1M | 81.2M | 78.6M | 81.8M | 2.17M | 7.26M |
| Current liabilities | 129.5M | 103.4M | 102.6M | 109.9M | 105.2M | 12.9M |
| Total debt | 1.65M | 4.37M | 4.81M | 3.04M | 490.7M | 160.0M |
| Total liabilities | 129.5M | 104.6M | 103.9M | 111.0M | 578.9M | 200.4M |
| Shareholders' equity | 416.4M | 525.0M | 783.2M | 1.24B | -233.9M | -154.2M |
| Shares outstanding | 389.7M | 396.9M | 381.4K | 360.4K | 396.9M | 396.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Cash from operations | -253.5M | -271.2M | -319.3M | -241.9M | -66.7M | -60.8M |
| Capital spending | -164.0K | -773.0K | -11.8M | -2.06M | -9.93M | -328.6K |
| Free cash flow | -253.7M | -272.0M | -331.1M | -244.0M | -76.6M | -61.2M |
| Cash from investing | -68.0M | 348.4M | -186.9M | 27.0M | -195.8M | 35.7M |
| Cash from financing | 169.0M | -4.87M | 15.8M | 240.5M | 311.5M | 19.5M |
| Share buybacks | 0 | 20.0M | ||||
| Change in cash | -154.1M | 72.9M | -487.3M | 888.6M | 51.7M | 27.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Next Day Disclosure Return | Nov 19, 2026 | Next day disclosure return | HKEX |
| INSIDE INFORMATION ANNOUNCEMENT COMPLETION OF THE H SHARE FULL CIRCULATION | Nov 19, 2026 | Other filings | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026 | Nov 3, 2026 | Monthly return | HKEX |
| Next Day Disclosure Return | Nov 2, 2026 | Next day disclosure return | HKEX |
| INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION | Nov 1, 2026 | Other filings | HKEX |
| Next Day Disclosure Return | Oct 27, 2026 | Next day disclosure return | HKEX |
| INSIDE INFORMATION ANNOUNCEMENT ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY | Oct 26, 2026 | Other filings | HKEX |
| Next Day Disclosure Return | Oct 26, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 23, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Oct 22, 2026 | Next day disclosure return | HKEX |
All 15 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON COMMERCIALISATION OF CORE PRODUCT YOCHANRA | Oct 22, 2026 | Operations update | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 5, 2026 | Monthly return | HKEX |
| INTERIM REPORT 2026 | Sep 21, 2026 | Interim report | HKEX |
| VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONAL THERAPY FOR PRETREATED AND PROGRESSED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHINA | Sep 18, 2026 | Operations update | HKEX |
| VOLUNTARY ANNOUNCEMENT INCLUSION OF YOCHANRA (TINENGOTINIB) IN THE CSCO GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF BILIARY TRACT CANCERS (2026) | Sep 18, 2026 | Other filings | HKEX |
Cap table
Built by 6ix from TransThera Sciences (Nanjing). Inc.’s releases
- Common shares
- 312,486,673
- Fully diluted
- 312,486,673
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 312,486,673 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 312,486,673 |
Log in to ask 6ix AI your own questions about TransThera Sciences (Nanjing). Inc.